$RNAC News

Last published 6d ago

6d agoRNACCartesian Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
6d agoRNACCartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 Retreatment data for Descartes-08 in MG
1w agoRNACCartesian Therapeutics Announces New Employment Inducement GrantGlobeNewswireFREDERICK, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today
2mo agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today
2mo agoRNACCartesian Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireFREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today
3mo agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today
3mo agoRNACCartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 Phase 2 TRITON trial of Descartes-08 in
4mo agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today
5mo agoRNACCartesian Therapeutics Announces New Employment Inducement GrantGlobeNewswireFREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced
5mo agoRNACCartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune DiseasesGlobeNewswireWestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple
5mo agoRNACCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027GlobeNewswireSecured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian's financial flexibility, further
6mo agoRNACCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQGlobeNewswireFREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced
6mo agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced
6mo agoRNACCartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireEnrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated Multiple patients enrolled in
7mo agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today
8mo agoRNACCartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireEnrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2
8mo agoRNACCartesian Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireFREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that
9mo agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the
10mo agoRNACCartesian Therapeutics Highlights Recent Progress and Outlines 2026 OutlookGlobeNewswireEnrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a
10mo agoRNACCartesian Therapeutics Announces the Appointment of Adrian Bot to Board of DirectorsGlobeNewswireFREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the
12mo agoRNACCartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into MyositisGlobeNewswire100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 patients
1y agoRNACCartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireEnrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected by end of year Initiation of Phase 2
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the
1y agoRNACCartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company's Board of DirectorsGlobeNewswireFREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantGlobeNewswireFREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the
1y agoRNACCartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
1y agoRNACCartesian Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireFREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that
1y agoRNACCartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireInitiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the
1y agoRNACCartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia GravisGlobeNewswireFREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today
1y agoRNACCartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQGlobeNewswireFREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that
1y agoRNACCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireInitiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., May 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases,
1y agoRNACCartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis TrialGlobeNewswireAfter a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases,
1y agoRNACCartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireFREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today
1y agoRNACCartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswirePhase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial Phase 2 trial of
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantGlobeNewswireFREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune
1y agoRNACCartesian Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireFREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune
1y agoRNACCartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia GravisGlobeNewswireFREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced
1y agoRNACCartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune DiseasesGlobeNewswirePhase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia gravis; Safety profile
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune
1y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune
1y agoRNACCartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 TrialGlobeNewswirePhase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative
1y agoRNACCartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease SummitGlobeNewswireFREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced
2y agoRNACCartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswireFREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune
2y agoRNACCartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireCompany expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety
2y agoRNACCartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual MeetingGlobeNewswireFREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced